Dr. Phil Febbo

Dr. Phil Febbo was appointed as Chief Medical Officer in March 2018. In this role, he is responsible for developing and executing the Company's medical strategy to accelerate genomic testing in order to improve health and healthcare. Dr. Febbo has a successful track record of translational research, clinical excellence, and for embedding molecular insights into clinical care.

Immediately before joining Illumina, Dr. Febbo served for 5 years as Chief Medical Officer of Genomic Health. Prior to Genomic Health, Dr. Febbo was a Professor of Medicine and Urology at the University of California, San Francisco (UCSF), where his laboratory focused on using genomics to understand the biology and clinical behavior of prostate cancer, and his clinical practice focused on genitourinary oncology.

Before joining the faculty of UCSF as an associate professor in 2010, Dr. Febbo worked at Duke University Medical Center's Institute of Genome Sciences and Policy. He completed his internal medicine residency at the Brigham and Women's Hospital, and his fellowship in oncology at the Dana-Farber Cancer Institute. After which he was an Attending Physician in the Genitourinary Oncology Center at Dana-Farber, Instructor at Harvard Medical School, and a post-doctoral fellow in Dr. Todd Golub's laboratory at Dana-Farber, as well as the Whitehead Institute Center for Genomic Research of MIT (now the Broad Institute). Throughout his career, Dr. Febbo participated in NCI-supported cooperative groups eventually serving as a primary investigator for the Translational Research Program of The Alliance, where his work focused on incorporating biomarkers into large clinical trials.

Dr. Febbo holds a Bachelor of Arts degree in Biology from Dartmouth College and an M.D. from UCSF. He has served on the Board of Varian Medical Systems and currently sits on the Board of the Regan-Udall Foundation of the Food and Drug Administration and the American College of Medical Genetics and Genomics Foundation

Sergio Villatoro Gómez

Dr. Sergio Villatoro is a molecular biologist with a large experience in the field of human genetics. His activity as scientist has been characterized by analyzing the human genomic variants either polymorphic or pathological, as well as the interaction among them. He ontained his PhD at Universitat Autonoma de Barcelona and he worked in several hospitals in Barcelona.

Currently, he is focused on assessing biomarkers by Next Generation Sequencing (NGS), in FFPE tissue or in cell-free DNA in order to figure out the best molecular diagnosis, follow-up and treatment of the disease for each patient.

As summary of his scientific production Dr. Sergio Villatoro is co-author of 20 articles published in international indexed journals, achieving an h index of 16 and an i10 index of 17. In addition, he has presented many scientific works as first author in different international meetings.

Elli Papaemmanuil

Dr Elli Papaemmanuil, PhD is an assistant professor at the Computational Oncology Service, Department of Epidemiology and Biostatistics at Memorial Sloan Kettering Cancer Center and is also serving as Associate Director for the Center of Hematological Malignancies. Dr Papaemmanuil earned her bachelor and masters degrees in human molecular genetics from the University of Glasgow, UK and a PhD in population genetics at the Institute of Cancer Research at the University of London. Her research involved the characterization of germline predisposition loci in childhood ALL by means of population genome wide association studies. Dr Papaemmanuil pursued postdoctoral research at the Wellcome Trust Sanger Institute under the mentorship of Peter Campbell where she led research into the discovery of cancer gene drivers of hematological neoplasms.

More recently, Dr Papaemmanuil has developed experimental and analytical methods to support molecular characterization of large patient cohorts and study the genetic and clinical inter-relationships of leukemias. She currently leads large population genomic profiling studies in myeloid neoplasms (AML, MDS, MPN) and in Acute Lymphoblastic Leukemia with the aim to characterize how the molecular architecture of the disease and the corresponding clonal relationships determine clinical phenotype and response to therapy.

She leads the computational oncology group for the center of heme malignancies at MSKCC and the pediatrics precision medicineinitiative where she oversees all molecularprofilingstudies in leukemia as well as all pediatric cancers.

Dr Papaemmanuil has published in top tier journals to include publications in NEJM, Nature Genetics, Nature Medicine, Blood. She is a Josie Robertson Investigator, a former ASH and EHA fellow, a recipient of the Damon Runyon Innovator grant as well as funding from the V Foundation, Gabrielle's angels foundation and Evans foundation amongst others.